General Information of Drug (ID: DMC38FO)

Drug Name
ZARDAVERINE Drug Info
Synonyms
zardaverine; 101975-10-4; Zardaverina; Zardaverinum; Zardaverine [INN]; Zardaverinum [INN-Latin]; UNII-TQ358GWH6Y; Zardaverina [INN-Spanish]; 6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE; C12H10F2N2O3; 6-(4-(Difluoromethoxy)-3-methoxyphenyl)-3(2H)-pyridazinone; TQ358GWH6Y; CHEMBL313842; CHEBI:46548; 6-[4-(difluoromethoxy)-3-methoxyphenyl]pyridazin-3(2H)-one; HJMQDJPMQIHLPB-UHFFFAOYSA-N; 6-(4-Difluoromethoxy-3-methoxyphenyl)-3(2H)-pyridazinone; NCGC00016106-04
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Terminated [1]
Cross-matching ID
PubChem CID
5723
ChEBI ID
CHEBI:46548
CAS Number
CAS 101975-10-4
TTD Drug ID
DMC38FO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 3 (PDE3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [3]
Oxtriphylline DMLHSE3 Cough MD12 Approved [3]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [4]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [5]
Olprinone DMWBQKU Heart failure BD10-BD13 Approved [6]
Inamrinone Lactate DMRMFP4 Cardiac disease BA00-BE2Z Approved [7]
Milrinone DM8TUPF Congestive heart failure BD10 Approved [3]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [8]
Tipelukast DMS9BDQ Asthma CA23 Phase 2 [9]
RPL-554 DMLD4VQ Allergic rhinitis CA08.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000057)
2 Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl.1991;34:379-402.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
5 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
6 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
7 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
8 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
9 Company report (MediciNova)
10 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.